glaxosmithkline is said to be axing around 110 employees in china for misconduct.with knowledge of the matter says it relates to wrongdoing more than 18 months ago. the drugmaker has been reviewing its operations in the country almost $480fined million by chinese authorities last year for bribing nongovernment personnel. the topa check on corporate headlines this hour. i am zeb eckert. the taxi sharing app uber is facing more problems in japan. it has been forced to close down its operation in a southwestern city after the government ruled it a legal. we've been taking a look into this. what is the problem for over? ber lets drivers without commercial transport licenses get involved in this program, and japan's transport ministry says that is the problem. on allowingban people without taxi licenses to make a profit out of those services. uber has argued, it's fine don't gete drivers paid directly by the passengers. still, japan's transport ministry saying that this is illegal. waysis saying it will find to construct this program in a way that meets official require

the top one at the moment, 2012, is glaxosmithkline, $3 billion. $1 billion criminal, $2 billion civil. off label promotions, failure to disclose safety data, kickbacks, false and misleading statements, reporting false prices and underpinning rebates owed under the medicaid -- it was a drug that ended up not being approved in the united states anyway. it is the kind of promotion that can happen many years before the drug comes on the market. brian: i found this on wikipedia, the list of the largest pharmaceutical settlements. the top one at the moment, 2012, is glaxosmithkline, $3 billion. $1 billion criminal, $2 billion civil. off label promotions, failure to disclose safety data, kickbacks, false and misleading statements, reporting false prices and underpinning rebates owed under the medicaid -- underpaying rebates owed under the medicaid program. did you follow that? dr. fugh-berman: i am a paid expert witness in several legal trials including one on plenty of -- including one. -- on avadia. those seem like large numbers, they are massive settlements but when you look at how much m

joining us is meg turrell and glaxosmithkline chairman of global vaccines. meg, start with you. you explain what this is? >> i will try and they'll correct me if i get it wrong. it's a fascinating new idea. we know about pills, injectable medicines. glaxo has been trying to think of a new way to deliver new medicine and treat disease. what they want to do is tap into electrical signals that govern all of the organ functions in our bodies. by doing that with really tiny devices, they'll be able to clip those on to nerves and control the things that are going wrong, the signals going to our organs causing disease or other things. they even talked about infertility as something they could potentially address with this. super fascinating. probably a few years off from market. >> can you give us an example of how this might be used, what the first application for this might be? >> well, if you take an example, for instance, when you have asthma, your muscles around your lungs get contracted and you can't breathe very well. we can control the nerves that control those messages as far

class of smithkline is asked -- glaxosmithkline is investigating misconduct. the british drugmaker has been reviewing its operations after being fined almost $480 million by chinese authorities for bribing nongovernment personnel. and china imports fell today lowest in over three years. shipman's were down more than 30% from january. many factories closed for the weeklong winter new year holiday. china caused nearly two thirds of the world's copper output last year. still to come, an apartment that helps you beat jet lag. we take you inside hong kong's healthiest home. after the break, china trades up strong. they record surplus. we will guess the investors view with our next guest right here on "asia edge." ♪ >> we want to take you live to these pictures from david -- from abreu dobby -- abu dhabi. this is one of two swiss pilots pioneering the first round the world solar flight. they will take turns flying the single seater 2300 kilogram claim that is -- plane that is powered only by the sun. the trip covers 35,000 kilometers and is expected to take five mon

. >> fda advisers will meet today to discuss glaxosmithkline's new asthma drug. it soothes the inner surface of breathing pathways. it may not feel like spring in some parts of the country, but it is now the official start of spring allergy season. the prolonged moisture in some areas of the u.s. have laid the groundwork for a bad allergy season. they recommend starting allergy medicine before the season hits which can reduce inflammation. a new generation of weight loss medications is facing some cautiousness, that's because there were safety issues with past diet drugs like fen-phen which had hard side effects. the latest drug approved by regulators last year, but it's not yet in pharmacies. sales of existing appetite suppressing drugs have been slower than expected. restricting the opening of new standalone fast food restaurants in los angeles did not curb obesity or diets as much as hoped. the law has been in effect since 2008. although they did limit unhealthy food, they didn't increase the healthy choices. while fast food restaurants were curbed delis snack

the top one at the moment, 2012, is glaxosmithkline, $3 billion. $1 billion criminal, $2 billion civil. off-label promotions, failure to disclose safety data, kickbacks, false and misleading statements, reporting false prices and underpinning rebates owed under the medicaid -- underpaying rebates owed under the medicaid program. did you follow that? dr. fugh-berman: i am a paid expert witness in several legal trials including one on avandia. those seem like large numbers, they are massive settlements but when you look at how much money drug companies have made the amount of money they have paid is quite small. and it takes so long for cases to make their way through the legal system that it is easy for companies to say that we do not do that anymore, nobody does that anymore, those are the bad old days, there were a few bad apples. although the tactics have changed, pharmaceutical companies are endlessly creative, but they are still promoting in ways legal and illegal. brian: on the same list there is a 2009 pfizer $2.9 billion off-label promotions and kickback. 2009, eli lilly $1.4 bi

they struck a deal with vaccine manufacturer glaxosmithkline, and they plan to offer inoculations for outline babies. it is an inflammation around the brain killing 10% of those inflicted >>> this week angelina jolie wrote an op eddetailing her choice to have preventive surgery to remove ovary and fallopian tunes. it was a follow up where she announced she tested positive to the b.r.c.a. gene. her chance of getting breast cancer increased to 87% and ovarian cancer 50%. she wrote: the article got a lot of attention, it got us wondering what there were. thanks to the affordable care act, if a woman meets guidelines they must pay. medicaid has the strictest criteria. in half. u.s. states medicaid doesn't cover the testing. most insurers cover the cost if a patient coughs a history of cancer. many will cover some of the costs if a woman has a close family member with a gene-causing mutation or if they have an ethic gene condition with scandanavian communities. a woman whose mother was diagnosed with breast cancer could carry the b.r.c.a. 1 or 2 mutations but not be qualified for the testi

license the new drugs to establish companies rather than become a full drugmaker like pfizer or glaxosmithklineenentech is one of the three best bay area companies to work for. "fortune" says goingle is the best in the united states, google wins for the sixth year in a row. sales force number eight and genentech number nine. >>> stocks wednesday we couldn't keep it in the green. by now you can tell me why. we've been over this a lot of times. we need the fed to get on with it. >>> alibaba has become the latest investor in snapchat. the new investment gives snapchat a paper value of $15 billion. this first reported by the "wall street journal". guys t also makes snapchat one of the most valuable tech startups there is. tesla's worth 24 but it's tesla, they make cars, $24 billion. snapchat 15. >> they reach a lot of young people advertising. >> for sure. >> thank you very much, scott. >>> 5:53 right now. march madness, can you feel it? it is a productivity killer for companies. reportedly. >> a report by challenger, gray and christmas suggests distracted workers could cost employers almost $2 bil

>> this was related to a act with savings portfolio of drugs of glaxosmithkline.petitive overlap there. that is why we come to this agreement. really in the best interests of patients making sure all of the drugs reach market best way possible. cheryl: one analyst we spoke to, bullish on company, but was a little concerned about potential for competition with these drugs that you're developing. how do you respond to that? >> we have six phase three trials going across both the wholly-owned drugs we own and drugs being developed with astrazeneca. five of those six programs we are first in class. so we will be first in those diseases. that includes not only melanoma, but lung cancer and, thyroid cancer as well as ovarian cancer. there is only one study we expect not to be first but we do have evidence that we may be best. that is the real promise. that is combination of two drugs that we own. what we found that when you put them together, the vulnerability is improved. cheryl: cocktail? >> when patients stay on drug they can benefit. cheryl: a billion doll to develo

glaxosmithkline is said to be axing around 110 employees in china for misconduct.ng than 18 months ago. the british drugmaker has been reviewing its operations in the country. after being fined $480 million by chinese authorities for bribing nongovernment personnel. luxury fashion market continues to shift from west to east. the italian label is making a comeback this week with a show in milan. >> malan is a long way from its roots. the designer and entrepreneur has built a successful fashion company at home in china that has annual sales of $400 million and plans to go public next year. krizia is her focus. >> i will try to keep the dna. ♪ born in 1954 and became famous for bucking mainstream trends. 26 collections in, and the brand hit its peak in the 1990's. times were not to last. it is survey day. -- it is her big day. the first collection is being shown in the lawn to a negro audience -- in milan to an eager audience. does she worry about selling that italian vision to a chinese audience? >> the chinese consumer needs to be educated and we need them to have f